The Pharmacology of Ibogaine: Targets, Kinetics, Metabolism

In laboratory tests, ibogaine attaches to many brain targets at once, each one fairly loosely [1]. In people, the gut wall and liver turn it into a second compound, noribogaine, using an enzyme called CYP2D6 [2]. Ibogaine leaves the blood within about a day. Noribogaine stays for days [2][3]. How fast this happens varies a great deal from person to person [4].

What kind of drug is ibogaine?

Ibogaine is a plant compound that, in lab tests, binds many brain targets at once [1][5]. It comes from the root bark of an African shrub, Tabernanthe iboga [5]. Chemists class it as an indole alkaloid [5].

A drug's pharmacology has three parts. Its targets are the receptors and pumps it attaches to. Its kinetics describe how fast it enters and leaves the blood. Its metabolism is what the body turns it into.

The target list comes from laboratory binding studies [1]. How the body absorbs, converts and clears ibogaine has been measured in people, both in patients and in healthy volunteers [2][4][6].

People weighing treatment often want to know how long the drug stays in the body. For most people, ibogaine itself is gone from the blood within a day [2]. Its main breakdown product, noribogaine, takes days to clear [3][7]. The overview of the wider evidence is in Ibogaine: What the Evidence Shows in 2026.

How does ibogaine work in the brain?

In lab tests, ibogaine binds to many brain targets at once, and holds each one loosely [1]. It binds to opioid receptors, the same family that heroin and morphine act on [1]. It binds to NMDA receptors, which respond to glutamate, the brain's main signal for switching nerve cells on [1]. It also binds nicotinic receptors, two serotonin receptors, and the pumps that clear serotonin and dopamine [1]. Sigma receptors are on the list too [5].

Most modern medicines work like a key cut for one lock. Ibogaine is more like a ring of keys. Each key fits several locks, none of them tightly. Its grip on each target is in the micromolar range, the unit chemists use for these bonds [1].

A loose grip matters only if enough drug reaches the target. In patients given a treatment dose, the free drug in the blood reaches that same micromolar range [5].

In rats, noribogaine, the compound the body makes from ibogaine, was about ten times as potent as ibogaine at raising serotonin [8].

Binding shows where ibogaine can act. Which contact causes which effect is a separate question. A 2019 research paper calls the route to its effect on drug-seeking unresolved [1]. In rodent research, these receptor contacts do not seem to explain the drug's long-lasting effects [1].

The candidate mechanisms for withdrawal relief are covered in How Ibogaine Interrupts Opioid Withdrawal. Work on simpler, engineered relatives of the molecule is in Beyond Ibogaine: Tabernanthalog and Engineered Analogs.

How is ibogaine metabolized?

The body turns ibogaine into noribogaine, mostly through one enzyme, CYP2D6 [2][9]. The work happens in the gut wall and the liver, soon after the drug is swallowed [2]. Two other enzymes, CYP2C9 and CYP3A4, play minor parts [5].

CYP2D6 is a busy enzyme. It also handles about 30 percent of the medicines in use today [5].

Think of CYP2D6 as a cutting tool. It snips a small chemical group off ibogaine, and the piece left behind is noribogaine [9]. In tests on human liver tissue, CYP2D6 did more than 95 percent of this work [9]. A liver sample from a person with little CYP2D6 activity managed only a slow version of the reaction [9].

Ibogaine peaks in the blood soon after it is swallowed. In patients given 500 to 1,000 mg by mouth, the peak came at about two hours [5]. In the Dutch patient study, a model fitted to blood samples put the typical peak within the first hour [4]. About two thirds of the drug rides on proteins in the blood, and the rest is free to reach its targets [5].

Noribogaine appears fast and peaks a few hours later. In healthy volunteers given a small test dose of ibogaine, it peaked at about four hours [6]. The Dutch model put the typical noribogaine peak at about seven and a half hours [4].

From there, the two compounds part ways. In people who process it at a normal or fast rate, more than 90 percent of ibogaine is gone from the blood a day after the dose [2]. Noribogaine is still high at that point [2][5].

Over the full course, the Dutch patients took in somewhat more noribogaine than ibogaine [4]. The body later changes noribogaine again, into a third compound called noribogaine glucuronide [4]. Levels of that third compound stayed low [4].

Why does CYP2D6 matter for ibogaine?

CYP2D6 sets how much ibogaine a person is exposed to, and for how long [4][6]. The gene for this enzyme comes in many versions, so its activity differs from one person to the next [4]. Between 5 and 10 percent of people of European descent lack the gene for CYP2D6 [11].

Picture two bathtubs filled with the same amount of water. One has a wide drain and one has a narrow drain. The same dose can leave very different amounts of drug behind, depending on the size of the drain.

The Dutch patient study measured this directly. Across the gene types in the group, the rate of ibogaine clearance varied more than tenfold [4]. In healthy volunteers given paroxetine, a medicine that blocks CYP2D6, ibogaine stayed in the blood for up to three days [6]. Its half-life stretched to about 10 hours [6]. Combined exposure to ibogaine and noribogaine roughly doubled [6].

Exposure also shapes the drug's effect on the heart. In cell studies, ibogaine blocks hERG, a potassium channel the heart uses to reset between beats [10]. It does so at levels found in the blood of treated patients [5].

In the Dutch study, the lengthening of the QT interval tracked ibogaine levels [4]. Slower CYP2D6 activity meant more ibogaine for longer [4].

Reported deaths after ibogaine often involve doses above 20 mg per kilogram, or several doses stacked over time [2]. The Dutch team calls for lower doses, ideally tailored to each person's CYP2D6 genes [4]. The volunteer study's authors suggest gene testing before treatment, and at least halving the dose for poor processors [6].

What is the half-life of ibogaine and noribogaine?

Ibogaine has a half-life of about 1.6 to 6 hours in the blood [2]. A half-life is the time the body takes to clear half of a dose. For most people, ibogaine is gone from the blood within 14 to 24 hours [2].

Noribogaine lasts far longer. Given on its own to healthy volunteers, it was absorbed quickly and peaked 2 to 3 hours after the dose [3]. Its half-life was 28 to 49 hours [3]. In people coming off methadone, the figure was 24 to 30 hours [7]. A single ibogaine dose therefore leaves noribogaine in the body for days [2][7].

Noribogaine also spreads widely beyond the blood into the body's tissues [3]. Picture a drop of dye in a wet sponge. Most of it soaks into the sponge, and only a little sits in the water around it.

In rats, ibogaine itself builds up in body fat, at levels far higher than in the blood or the brain [5].

The long tail is active. Given alone to patients, noribogaine lengthened the QT interval, and the effect grew with the dose [7]. At the highest dose, the average peak rise was about 42 milliseconds [7]. After an ibogaine dose, QT lengthening lasted beyond 24 hours in close to half the patients in one study [12].

Repeat doses add up. Taking several doses over time raises the total amount of noribogaine in the blood, which leads to very high levels of both compounds [2]. The full picture of the metabolite is in Noribogaine: Pharmacokinetics of the Long Tail.

What does ibogaine do to the body?

The effects of ibogaine follow its levels in the blood [2][4]. A vivid, dream-like stage begins between about half an hour and three hours after the dose [2][13]. It lasts about 4 to 8 hours [2][13].

For most people in St Kitts, the visions stopped quite suddenly, 6 to 8 hours after the dose [2]. The researchers tie that timing to how fast each person clears ibogaine [2]. A quieter, inward stage comes next. People spend it thinking over what came up, and it can last 8 to 20 hours [2][13].

Body chemistry changes the ride. Two people in St Kitts cleared ibogaine so fast that blood tests could not find it [2]. Neither had the dream-like state [2]. The same team reports that people who lack CYP2D6 had a much stronger experience, lasting up to a full day [2].

The body feels it too. Nausea, vomiting and unsteady walking were the most common side effects in St Kitts [2]. About one person in twenty had a drop in blood pressure on standing up [2].

In a Dutch hospital study, every patient had a spell of severe, short unsteadiness and could not walk without help [12]. That unsteadiness tracked ibogaine levels, not noribogaine levels [4]. Heart rate slowed during treatment as well [12]. In earlier heart monitoring of treated patients, about one in seven had a markedly slow heartbeat [5].

Some people still felt mild effects a day after the dose, and these soon faded [2]. Sleep is often hard for up to three days, and sleep medicine helps [13].

Noribogaine has also been given on its own. In that trial, the most common effects were changes in how light looked, about an hour after the dose, along with headache and nausea [7]. Results from each human study are in Every Major Ibogaine Study, Summarized.

Where the research goes next

Four directions stand out. The first is dose. In the Dutch patient study, peak ibogaine levels ran more than ten times higher than the level that produced half the maximum QT effect [4]. The team calls for trials of much lower doses, to learn whether those still ease withdrawal [4].

The second is dosing by genes. Both human CYP2D6 studies point toward testing each person's CYP2D6 genes before treatment and setting the dose to match [4][6]. A trial that does this would show whether it evens out exposure in practice.

The third is separating parent drug from metabolite. Noribogaine given alone produced a trend toward lower withdrawal scores that did not reach statistical significance [7]. The same team planned multiple-dose noribogaine studies with exposure kept under control [7].

The fourth is linking targets to effects in people. The receptor list is long, and which contacts drive the effect on drug-seeking is still an open question [1]. The wider research agenda is in Open Questions: What Rigorous Ibogaine Trials Must Answer.

Frequently asked questions

Is ibogaine an opioid?

No. Ibogaine is a plant compound from the root bark of an African shrub [5]. In lab tests it binds opioid receptors, along with many other targets [1]. In healthy volunteers, noribogaine did not shrink the pupils or dull pain the way opioids do [3].

What receptors does ibogaine work on?

In lab studies, ibogaine binds to opioid, NMDA, nicotinic and serotonin receptors [1]. It also binds the pumps that clear serotonin and dopamine [1], and sigma receptors [5]. Each bond is loose [1].

How long does ibogaine stay in the body?

For most people, ibogaine leaves the blood within a day [2]. Noribogaine stays for days, with a half-life of one to two days across two trials [3][7]. People with low CYP2D6 activity keep ibogaine longer [6].

How long do ibogaine's effects last?

The vivid, dream-like stage usually lasts 4 to 8 hours [2]. A quieter, reflective stage of 8 to 20 hours follows [13]. Poor sleep can continue for up to three days [13].

What does ibogaine do to the heart?

Ibogaine slows the heart's electrical reset between beats [12]. Doctors measure this as the QT interval. In a Dutch hospital study, it rose by about 95 milliseconds at its peak [12]. Half the patients passed 500 milliseconds [12]. Treatment requires screening and constant heart monitoring, which lower the risk without removing it [2][12].

Do other medicines change how ibogaine is processed?

Yes. Medicines that block CYP2D6 slow the breakdown of ibogaine [6]. In volunteers taking the antidepressant paroxetine, total exposure to the two compounds about doubled [6]. A Dutch hospital study kept out anyone on drugs that affect CYP2D6 or the QT interval [12].